Mucormycosis – resurgence of a deadly opportunist during COVID-19 pandemic: Four case reports  

作　　者：Shalini Upadhyay Tanisha Bharara Manisha Khandait Ankit Chawdhry Bharat Bhushan Sharma 

机构地区：[1]Department ofMicrobiology,SGT University,Gurugram 122505,Haryana,India [2]Department of Oral and Maxillofacial Surgery,SGT University,Gurugram 122505,Haryana,India [3]Department of Radiology,SGT University,Gurugram 122505,Haryana,India

出　　处：《World Journal of Clinical Cases》2021年第36期11338-11345,共8页世界临床病例杂志

摘　　要：BACKGROUND Coronavirus disease 2019(COVID-19)patients who suffer severe infection or comorbidities have an increased risk of developing fungal infections.There is a possibility that such infections are missed or misdiagnosed,in which case patients may suffer higher morbidity and mortality.COVID-19 infection,aggressive management strategies and comorbidities like diabetes render patients prone to opportunistic fungal infections.Mucormycosis is one of the opportunistic fungal infections that may affect treated COVID patients.CASE SUMMARY We present a case series of four adult males who were diagnosed with mucormycosis post-COVID-19 recovery.All the patients had diabetes and a history of systemic corticosteroids for treatment of COVID-19.The mean duration between diagnosis of COVID-19 and development of symptoms of mucor was 15.5±14.5(7–30)d.All patients underwent debridement and were started on antifungal therapy.One patient was referred to a higher center for further management,but the others responded well to treatment and showed signs of improvement at the last follow-up.CONCLUSION Early diagnosis and management of mucormycosis with appropriate and aggressive antifungals and surgical debridement can improve survival.

关 键 词：ZYGOMYCETES Fungal infection COVID-19 co-infection Diabetes mellitus Case series Case report 

分 类 号：R519[医药卫生—内科学] R563.1[医药卫生—临床医学]